Artelo Biosciences (ARTL) Price & Analysis

Compare

523 Followers

ARTL Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.20 - $28.60

Previous CloseN/A

Volume8.82K

Average Volume (3M)114.47K

Market Cap

$5.75M

Enterprise Value$6.43M

Total Cash (Recent Filing)$2.07M

Total Debt (Recent Filing)$896.00K

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Nov 18, 2025

EPS Estimate

-4.92

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.61

Shares Outstanding1,321,552

10 Day Avg. Volume75,670

30 Day Avg. Volume114,465

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.12

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-0.61

Forecast

1Y Price Target

$20.00

Price Target Upside359.77% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical MilestonesArtelo's pipeline candidates are slated to reach important clinical milestones, which are underappreciated.

Investigational DrugART27.13 is emerging as a high-value investigational drug, as no therapies have proven to be safe treatments and approved for cancer-related cachexia.

Bears Say

Investment RisksInvestment thesis risks include failure of clinical trials to prove efficacy and potential need to raise additional funds.

Artelo Biosciences News

Artelo prices 640,924 shares at $4.40 in underwritten public offering

Artelo Biosciences (ARTL) announced the pricing of its previously announced underwritten public offering of 640,924 shares of its...

2d ago

ARTL

Artelo Biosciences announces common stock, warrant offering, no amount given

Artelo Biosciences (ARTL) announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants....

3d ago

ARTL

Artelo does not envision need to internally fund Phase 3 trial of ART27.13

Artelo Biosciences (ARTL) affirms that, based on the strength of the positive interim results from its Phase 2...

3d ago

ARTL

Artelo Biosciences announces interim Phase 2 CAReS results

Artelo Biosciences (ARTL) announced interim results from its Phase 2 Cancer Appetite Recovery Study trial with ART27.13, the...

3d ago

ARTL

Artelo Biosciences announces data on food effect evaluation with ART26.12

Artelo Biosciences (ARTL) announced encouraging results from its preliminary food effect evaluation with ART26.12. This assessment was conducted...

12d ago

ARTL

Artelo Biosciences reports Q2 EPS ($5.61) vs. ($4.52) last year

Gregory D. Gorgas, President and CEO of Artelo Biosciences (ARTL), commented on the results of the second quarter,...

24d ago

ARTL

Artelo Biosciences receives notice of allowance from European patent office

Artelo Biosciences (ARTL) announced that the European Patent Office has issued a Notice of Allowance for Artelo’s European...

26d ago

ARTL

Artelo Biosciences Approves Common Stock Increase

An update from Artelo Biosciences ( ($ARTL) ) is now available. On August 28, 2025, Artelo Biosciences held...

8d ago

ARTL

Artelo Biosciences Ends Securities Purchase Agreement

An update from Artelo Biosciences ( ($ARTL) ) is now available. Artelo Biosciences, Inc. recently terminated two significant...

17d ago

ARTL

Artelo Biosciences Reports Increased Losses Amid Strategic Investments

Artelo Biosciences ( ($ARTL) ) has released its Q2 earnings. Here is a breakdown of the information Artelo...

23d ago

ARTL

Artelo Biosciences Partners with ABK Labs for Strategic Growth

Artelo Biosciences ( ($ARTL) ) has issued an announcement. On August 1, 2025, Artelo Biosciences, Inc. entered into...

30d ago

ARTL

Artelo Biosciences announces private placement to initiate Solana treasury

Artelo entered into a securities purchase agreement for an at-the market PIPE for the purchase and sale of...

1M ago

ARTL

Artelo Biosciences receives MHRA guidance for Phase 1 trial of ART12.11

Artelo Biosciences (ARTL) has received written scientific advice from the UK’s Medicines and Healthcare products Regulatory Agency on...

1M ago

ARTL

Artelo Biosciences Announces At-The-Market Offering Agreement

The latest update is out from Artelo Biosciences ( ($ARTL) ). On July 18, 2025, Artelo Biosciences entered...

2M ago

ARTL

ARTL FAQ

What was Artelo Biosciences Inc’s price range in the past 12 months?

Artelo Biosciences Inc lowest stock price was $4.20 and its highest was $28.60 in the past 12 months.

What is Artelo Biosciences Inc’s market cap?

Artelo Biosciences Inc’s market cap is $5.75M.

When is Artelo Biosciences Inc’s upcoming earnings report date?

Artelo Biosciences Inc’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.

How were Artelo Biosciences Inc’s earnings last quarter?

Artelo Biosciences Inc released its earnings results on Aug 13, 2025. The company reported -$5.61 earnings per share for the quarter, beating the consensus estimate of -$25.14 by $19.53.

Is Artelo Biosciences Inc overvalued?

According to Wall Street analysts Artelo Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Artelo Biosciences Inc pay dividends?

Artelo Biosciences Inc does not currently pay dividends.

What is Artelo Biosciences Inc’s EPS estimate?

Artelo Biosciences Inc’s EPS estimate is -4.92.

How many shares outstanding does Artelo Biosciences Inc have?

Artelo Biosciences Inc has 1,321,552 shares outstanding.

What happened to Artelo Biosciences Inc’s price movement after its last earnings report?

Artelo Biosciences Inc reported an EPS of -$5.61 in its last earnings report, beating expectations of -$25.14. Following the earnings report the stock price went up 4.218%.

Which hedge fund is a major shareholder of Artelo Biosciences Inc?

Currently, no hedge funds are holding shares in ARTL

Company Description

Artelo Biosciences Inc

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Artelo Biosciences (ARTL) Earnings & Revenues

Historic Earnings Reports

ARTL Stock 12 Month Forecast

Average Price Target

$20.00

▲(359.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.953846153846154,11.707692307692307,12.461538461538462,13.215384615384615,13.96923076923077,14.723076923076924,15.476923076923077,16.23076923076923,16.984615384615385,17.73846153846154,18.49230769230769,19.246153846153845,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.953846153846154,11.707692307692307,12.461538461538462,13.215384615384615,13.96923076923077,14.723076923076924,15.476923076923077,16.23076923076923,16.984615384615385,17.73846153846154,18.49230769230769,19.246153846153845,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.2,10.953846153846154,11.707692307692307,12.461538461538462,13.215384615384615,13.96923076923077,14.723076923076924,15.476923076923077,16.23076923076923,16.984615384615385,17.73846153846154,18.49230769230769,19.246153846153845,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.15,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.22,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >